9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 46

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: Has Results

Outcome Measures: 24 Week Progression Free Survival,  Number of Participants With Overall Tumor Response,  Overall Survival, Progression Free Survival

Interventions: dasatinib,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: February 2010

Completion Date: December 2012

Last  Posted Date: August 11, 2016

Location: Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT00509041

Was this article helpful?
Dislike 0